Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Overview (11 minutes)
  • CME
  • CE

Overview and recognition of migraine as a clinical syndrome.
Jessica Ailani, MD
Robert G. Kaniecki, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Released: March 25, 2020 Expiration: March 24, 2021

This program is divided into short segments that you can review from the Activity landing page. After reviewing all segments, click the Claim Credit button to complete the CME posttest and evaluation.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Consider frequent/chronic migraine as a clinical syndrome with a range of symptomatic, quality of life, and comorbid features
  • Identify common challenges with available pharmacotherapies that impede effective management of episodic and chronic migraine
  • Describe the role of CGRP in the immunopathogenesis of migraine and the evidence for effective reduction of migraine occurrence and improved measures of quality of life with CGRP receptor blockers
  • Describe the potential place in therapy of quarterly infusion and gepant CGRP blockers for migraine management
  • Differentiate the mechanism of action of the selective serotonin 5-HT1F agonist “ditan” class and respective safety profile from that of the triptan abortive therapies
  • Apply current guidelines and updated data in the optimal management of episodic and chronic migraine

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:


Jessica Ailani, MD

MedStar Georgetown Headache Center
Professor of Clinical Neurology
Department of Neurology
MedStar Georgetwon University Hospital
Washington, DC

Jessica Ailani, MD, FAHS, FAAN, has disclosed that she has received consulting fees from Allergan, Amgen, Biohaven, Health Monitor, Impel, Lilly, Lundbeck, Neurodiem, Revance, Satsuma, Teva, Theranica, and Zosano; funds for research support paid to her institution from Allergan, American Migraine Foundation, Biohaven, Lilly, and Zosano; and fees for non-CME/CE services from Allergan, Amgen, Biohaven, Lilly, Lundbeck, and Teva.
Robert G. Kaniecki, MD

Director, UPMC Headache Center
Chief, Headache Division
Director, Headache Fellowship Training Program
Assistant Director, Neurology Residency Training Program
Associate Professor of Neurology
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Robert Kaniecki, MD, has no relevant financial relationships to disclose.


Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
David C. Howard

Editorial Contributor

David Howard, PharmD, has no relevant conflicts of interest to report.
Anne Roc, PhD
Director, Scientific Services
Anne Roc, PhD, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, NP, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for neurologists, neurology residents, headache and pain specialists, primary care physicians, nurse practitioners, physician assistants, and other healthcare providers who treat patients with migraine.


The goal of this activity is to improve the knowledge and competence of learners to apply current and emerging targeted treatment strategies in the management of patients with episodic and chronic migraine.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 25, 2020, through March 24, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Patient cases on migraine prophylaxis: beta-blockers, antiseizure medications, CGRP monoclonal antibodies (mAbs), role of shared decision-making

Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: May 28, 2020 Expired: May 28, 2021

Patient cases on comorbidities in migraine, including sleep disorders, depression, and more

Jessica Ailani, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: May 28, 2020 Expired: May 28, 2021

Expert commentary on new monoclonal antibodies that target CGRP for the prevention of chronic migraine from CCO

Jessica Ailani, MD Released: April 9, 2020

Expert commentary from CCO on the evolving management of acute and preventive migraine treatment and the promise of anti-CGRP therapies

Robert G. Kaniecki, MD Released: March 26, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by educational grants from

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?